Protara Therapeutics
TARA
59 hedge funds and large institutions have $124M invested in Protara Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 9 closing their positions.
363% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $478K
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 60 → 59 (-1)
8.24% less ownership
Funds ownership: 86.45% → 78.22% (-8.2%)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
21% less capital invested
Capital invested by funds: $157M → $124M (-$32.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$6.77M |
| 2 |
SC
Stempoint Capital
New York
|
+$3.83M |
| 3 |
BlackRock
New York
|
+$2.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.9M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$11M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.75M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.85M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.09M |
TARA Hedge Fund Activity: Q1 2025 in Review
59 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2025, worth a combined $124M — down 21% from $157M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TARA and 8 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 24 added.
The largest buyer was Janus Henderson Group, adding an estimated $6.77M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $11.9M sold.
- 59 institutional investors held Protara Therapeutics (TARA) as of Q1 2025, down from 60 in Q4 2024.
- Funds reported $124M of Protara Therapeutics stock for Q1 2025, down 21% quarter-over-quarter.
- 8 funds opened new Protara Therapeutics positions in Q1 2025 and 9 closed out, a net change of -1 holder.
- The largest Protara Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $6.77M added.
- The largest Protara Therapeutics seller in Q1 2025 was Adage Capital Partners, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2025.